Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper 1 - NSCLC, metastatic

6256 - IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC


27 Sep 2019


Proffered Paper 1 - NSCLC, metastatic


Tumour Site

Non-Small Cell Lung Cancer


David Spigel


Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394


D. Spigel1, F. de Marinis2, G. Giaccone3, N. Reinmuth4, A. Vergnenegre5, C.H. Barrios6, M. Morise7, E. Felip8, Z.G. Andric9, S. Geater10, M. Özgüroğlu11, S. Mocci12, M. McCleland12, I. Enquist12, K.M. Komatsubara12, Y. Deng12, H. Kuriki12, X. Wen12, J. Jassem13, R.S. Herbst14

Author affiliations

  • 1 Tennessee Oncology, Sarah Cannon Research Institute, 37203 - Tennessee/US
  • 2 Division Of Thoracic Oncology, European Institute of Oncology, 20141 - Milan/IT
  • 3 Oncology, Lombardi Cancer Center Georgetown University, 20007 - Washington DC/US
  • 4 Thoracic Oncology Department, Asklepios Lung Clinic, 82131 - Munich-Gauting/DE
  • 5 Uotc Department- Unité Oncologie Thoracique Et Cutanée, CHU Limoges - Hopital Dupuytren, 87042 - Limoges/FR
  • 6 School Of Medicine, PUCRS-Pontifícia Universidade do Rio Grande do Sul, 90619-900 - Porto Alegre/BR
  • 7 Department Of Respiratory Medicine, Nagoya University, Graduate School of Medicine, 466-8550 - Nagoya/JP
  • 8 Medical Oncology Service (lung Cancer Unit), Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 9 Medical Oncology Dep., Clinical Hospital Center Bezanijska Kosa, 11080 - Belgrade/RS
  • 10 Intermal Medicine, Faculty Of Medicine, Prince of Songkla University, 90110 - Hat Yai, Songkhla/TH
  • 11 Department Of Internal Medicine, Istanbul University - School of Medicine, Istandul/TR
  • 12 Global Product Development Medical Affairs, Genentech, Inc., South San Francisco/US
  • 13 Clinical Oncology And Radiotherapy, Medical University of Gdansk, 80-211 - Gdansk/PL
  • 14 Medical Oncology, Yale University School of Medicine, 06520 - New Haven/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 6256


PD-L1/PD-1 inhibitors (CPI) as monotherapy or combined with platinum-based doublet chemo (± bevacizumab) are 1L tx options in metastatic NSCLC, with choice of agent(s) determined by PD-L1 expression. For patients (pts) who may be ineligible for combination therapy, CPI monotherapy remains an attractive tx choice. IMpower110 evaluated atezo as 1L tx in PD-L1–selected pts independent of tumour histology.


IMpower110 enrolled 572 chemo-naive pts with stage IV nonsquamous (nsq) or squamous (sq) NSCLC, PD-L1 expression ≥ 1% on TC or IC, measurable disease by RECIST 1.1 and ECOG PS 0-1. Pts were randomised 1:1 to receive atezo 1200 mg IV q3w (Arm A) or platinum-based chemo (Arm B; 4 or 6 21-day cycles). Arm B nsq pts received cisplatin (cis) 75 mg/m2 or carboplatin (carbo) AUC 6 + pemetrexed 500 mg/m2 IV q3w; Arm B sq pts received cis 75 mg/m2 + gemcitabine (gem) 1250 mg/m2 or carbo AUC 5 + gem 1000 mg/m2 IV q3w. Stratification factors were sex, ECOG PS, histology and tumour PD-L1 status. The primary endpoint of OS is tested hierarchically in wild-type (WT; EGFR/ALK-negative) pts (TC3 or IC3 then TC2/3 or IC2/3 then TC1/2/3 or IC1/2/3).


The 3 primary efficacy populations included 554 TC1/2/3 or IC1/2/3 WT pts, 328 TC2/3 or IC2/3 WT pts and 205 TC3 or IC3 WT pts. In the TC3 or IC3 WT population, atezo monotherapy improved median OS by 7.1 mo (HR, 0.595; P = 0.0106) vs chemo (Table); median follow-up was 15.7 mo. The safety population comprised 286 pts in Arm A and 263 pts in Arm B. Treatment-related AEs (TRAEs) and Grade 3-4 TRAEs occurred in 60.5% (Arm A) and 85.2% (Arm B), and 12.9% (Arm A) and 44.1% (Arm B), respectively.Table:


Median OS
Arm A (atezo)Arm B (chemo)HRa 95% CIP valuea
TC3 or IC3 WT10720.29813.10.595 (0.398, 0.890)0.0106
TC2/3 or IC2/3 WT16618.216214.90.717 (0.520, 0.989)0.0416
TC1/2/3 or IC1/2/3 WT27717.527714.10.832 (0.649, 1.067)0.1481b

IC, tumour-infiltrating immune cells; TC, tumour cells. PD-L1 expression was centrally evaluated with the VENTANA SP142 IHC assay. TC3 or IC3 = TC ≥ 50% or IC ≥ 10% PD-L1+; TC2/3 or IC2/3 = TC ≥ 5% or IC ≥ 5% PD-L1+; TC1/2/3 or IC1/2/3 = TC ≥ 1% or IC ≥ 1% PD-L1+.




Only for descriptive purposes.


At this interim analysis, IMpower110 met the primary OS endpoint with statistically significant and clinically meaningful improvement in the TC3 or IC3 WT population. The safety profile favoured Arm A, with no new or unexpected safety signals seen.

Clinical trial identification


Editorial acknowledgement

Medical writing assistance was provided by Kia C. E. Walcott, PhD, of Health Interactions and funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche.


F. Hoffmann-La Roche.


D. Spigel: Research grant / Funding (self): F. Hoffmann-La Roche . F. de Marinis: Research grant / Funding (institution): F. Hoffmann-La Roche. G. Giaccone: Research grant / Funding (institution): F. Hoffmann-La Roche. N. Reinmuth: Research grant / Funding (institution): F. Hoffmann-La Roche; Honoraria (self): BMS, Boehringer, AstraZeneca, MSD, Takeda, Pfizer, Merk. A. Vergnenegre: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: F. Hoffmann-La Roche, BMS, MSD, AstraZeneca. C.H. Barrios: Research grant / Funding (institution): Bristol Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Pfizer, Novartis, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche/Genentech, Lilly, Sanofi, Taiho Pharmaceutical, Mylan, Merrimack, Merck, Abbvie, Astellas Pharma, Biomarin, Bristol-Myers Squibb, Daiichi Sankyo, Abraxis BioScience, AB Sc. M. Morise: Research grant / Funding (institution): F. Hoffmann-La Roche; Honoraria (self), Speaker Bureau / Expert testimony: Eli Lilly, Chugai, AstraZeneca, Ono, Pfizer, MSD, ; Research grant / Funding (institution): Chugai, AstraZeneca, Pfizer, Merk Serono, Kissei, Taiho, Novartis; Research grant / Funding (institution): Boehringer Ingelheim. E. Felip: Advisory / Consultancy, Speaker Bureau / Expert testimony: ABBVIE; Advisory / Consultancy, Speaker Bureau / Expert testimony: Astra Zeneca; Advisory / Consultancy: BergenBio; Advisory / Consultancy: Blue Print Medicines; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Meyers Squibb; Advisory / Consultancy: Celgene; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy: Guardant Health; Advisory / Consultancy: Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony: Medscape; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck KGaA; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy: Prime Oncology; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy: Samsung; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advisory / Consultancy: Touchtime. Z.G. Andric: Research grant / Funding (institution): F. Hoffmann-La Roche. S. Geater: Research grant / Funding (institution): F. Hoffmann-La Roche. M. Özgüroğlu: Research grant / Funding (institution): F. Hoffmann-La Roche. S. Mocci: Full / Part-time employment: Roche/GNE. M. McCleland: Full / Part-time employment: Roche/GNE. I. Enquist: Full / Part-time employment: Roche/GNE. K.M. Komatsubara: Full / Part-time employment: Roche/GNE. Y. Deng: Full / Part-time employment: Roche/GNE. H. Kuriki: Research grant / Funding (institution): Roche/GNE; Shareholder / Stockholder / Stock options, Full / Part-time employment: Chugai Pharmaceutical. X. Wen: Full / Part-time employment: Roche/GNE. J. Jassem: Speaker Bureau / Expert testimony, Research grant / Funding (institution): F. Hoffmann-La Roche ; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: BMS; Advisory / Consultancy: MSD; Advisory / Consultancy: Takeda. R.S. Herbst: Honoraria (self): Roche/Genentech; Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Merck; Honoraria (self), Research grant / Funding (institution): Eli Lilly and Company; Honoraria (self): Abbvie Pharmaceuticals; Honoraria (self): ARMO Biosciences; Honoraria (self): Biodesix; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): EMD Serrano; Honoraria (self): Genmab; Honoraria (self): Halozyme; Honoraria (self): Heat Biologics; Honoraria (self): Infinity Pharmaceuticals; Honoraria (self): Loxo Oncology; Honoraria (self): Merck and Company ; Honoraria (self): Nektar; Honoraria (self): Neon Therapeutics; Honoraria (self): NextCure; Officer / Board of Directors, non-executive/independent: Junshi Pharmaceticals; Honoraria (self): Sanofi; Honoraria (self): Seattle Genetics; Honoraria (self): Shire PLC; Honoraria (self): Spectrum Pharmaceuticals; Honoraria (self): Symphogen; Honoraria (self): Tesaro; Honoraria (self): Tocagen.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.